Interleukin-6 limits host susceptibility to urinary tract infection by promoting urothelial expulsion of intracellular bacteria
Journal of Innate Immunity · 2026
DOI: 10.1159/000550787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innate Immunity, 2026. Verfasst von Sudipti Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kidney and Urinary Tract Center, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Interleukin-6, Urinary Tract Infections, Uropathogenic Escherichia coli, Escherichia coli Infections. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Introduction
Interleukin (IL)-6 has an important role in limiting urinary tract infection (UTI). Mice lacking IL-6 are more susceptible to uropathogenic Escherichia coli (UPEC), including increased formation of intracellular bacterial communities (IBCs). How IL-6 promotes UPEC clearance is unknown. We hypothesize IL-6 reduces UTI susceptibility by limiting IBC formation through early mechanism of infection.
Methods
Female mice were treated with vehicle or neutralizing antibodies to inhibit IL-6 or the IL-6 receptor (IL-6R) prior to transurethral UPEC infection. In rescue experiments, murine recombinant (r)IL-6 was administered to IL-6 knockout (KO) mice. Bladder IBCs, urinary and bladder bacterial burden, and UPEC expulsion were quantified. For clinical translation, human urothelial cells were pretreated with human rIL-6 and infected with UPEC. Bacterial attachment, invasion, and expulsion were quantified.
Results
Neutralization of IL-6 or IL-6R increased bladder IBC counts compared to isotype controls. Similarly, while IL-6 KO mice exhibited higher IBC counts than wild-type controls, this phenotype was reversed by rIL-6 administration. Gentamicin protection assays confirmed increased intracellular UPEC burden and reduced bacterial expulsion in IL-6 KO bladders. Recombinant IL-6 treatment enhanced UPEC expulsion in human urothelial cells without impacting bacterial attachment or invasion.
Conclusion
IL-6 facilitates UPEC expulsion, limiting intracellular UPEC early in infection and thus the initial formation of IBCs. Since IBC formation is a bottleneck in UPEC survival during UTI, these findings identify a mechanism whereby IL-6 reduces early UPEC urothelial infectivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kidney and Urinary Tract Center, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatric Urology, Department of Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Division of Nephrology and Hypertension, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Kidney and Urinary Tract Center, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA, christina.ching@nationwidechildrens.org.
- Department of Pediatric Urology, Department of Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA, christina.ching@nationwidechildrens.org.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Gupta, S., Rajak, S., Cortado, H., Becknell, B., Spencer, J. D., & Ching, C. B. (2026). Interleukin-6 limits host susceptibility to urinary tract infection by promoting urothelial expulsion of intracellular bacteria. Journal of Innate Immunity. https://doi.org/10.1159/000550787
Vancouver
Gupta S, Rajak S, Cortado H, Becknell B, Spencer JD, Ching CB. Interleukin-6 limits host susceptibility to urinary tract infection by promoting urothelial expulsion of intracellular bacteria. Journal of Innate Immunity. 2026. doi:10.1159/000550787
BibTeX
@article{Gupta2026,
author = {Gupta, Sudipti and Rajak, Shradha and Cortado, Hanna and Becknell, Brian and Spencer, John David and Ching, Christina Barbara},
title = {Interleukin-6 limits host susceptibility to urinary tract infection by promoting urothelial expulsion of intracellular bacteria},
journal = {Journal of Innate Immunity},
year = {2026},
doi = {10.1159/000550787}
}
EUVIMED